Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

BACKGROUND: Sorafenib is a multi-kinase inhibitor with activity against fms-like tyrosine kinase 3 with internal tandem duplication mutation and Raf kinase among others. A phase I dose escalation study of sorafenib was conducted in patients with advanced myelodysplastic syndrome and relapsed or refr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Borthakur, Gautam, Kantarjian, Hagop, Ravandi, Farhad, Zhang, Weiguo, Konopleva, Marina, Wright, John J., Faderl, Stefan, Verstovsek, Srdan, Mathews, Sheela, Andreeff, Michael, Cortes, Jorge E.
Formato: Artigo
Idioma:Inglês
Publicado em: Ferrata Storti Foundation 2011
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3012766/
https://ncbi.nlm.nih.gov/pubmed/20952518
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2010.030452
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados